The MAPK pathway across different malignancies: A new perspective
By Mauricio Burotto, Victoria L. Chiou, Jung-Min Lee, E. C. Kohn. Cancer, 2014
911 citations recorded by the source corpus.
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway is activated by upstream genomic events and/or activation of multiple signaling events in which information coalesces at this important nodal pathway point. This pathway is tightly regulated under normal conditions by phosphatases and bidirectional communication with other pathways, like the protein kinase B/mammalian target of rapamycin (AKT/m‐TOR) pathway. Recent evidence indicates that the MAPK/ERK signaling node can function as a tumor suppressor as well as the more common pro‐oncogenic signal. The effect that predominates depends on the intensity of the signal and the context or tissue in which the signal is aberrantly activated. Genomic profiling of tumors has revealed common mutations in MAPK/ERK pathway components, such as v‐raf murine sarcoma viral oncogene homolog B1 (BRAF). Currently approved for the treatment of melanoma, inhibitors of BRAF kinase are being studied alone and in combination with inhibitors of the MAPK and other pathways to optimize the treatment of many tumor types. Therapies targeted toward MAPK/ERK components have various response rates when used in different solid tumors, such as colorectal cancer and ovarian cancer. Understanding the differential nature of activation of the MAPK/ERK pathway in each tumor type is critical in developing single and combination regimens, because different tumors have unique mechanisms of primary and secondary signaling and subsequent sensitivity to drugs. Cancer 2014;120:3446–3456. © 2014 American Cancer Society.
Subfields: Molecular Biology, Organic Chemistry
View Paper: https://www.semanticscholar.org/paper/bffdedbd164a524d1389f944400ee3d4692e2902
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, background): “MAPK signaling pathways, as ubiquitous signal transduction, regulate almost all aspects of cellular function in cancers.(157,171) For cell proliferation mediated by CAFs in MAPK signal, endometrial cancer cell proliferation was prompted significantly by CAF-CM compared to NF-CM through the phosphory”
- A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer (2019, background): “1%, lung cancer: 12–30% and BRAF: 50–60 in melanoma; colorectal: 5–20%, lung cancer: 4%), whilst mutations in MEK (MAP kinse-ERK kinase) or ERK (extracellular regulated MAP kinase) are identified less (melanoma 3–8%, colorectal 3%) or rarely, respectively [28].”